BioSpace News Archive

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 17 new abstracts from across its neuroscience portfolio at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies (APSS).

Active Biotech and its partner NeoTX announce the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox, in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer who have been previously treated with chemotherapy and checkpoint inhibitors.

Aadi Bioscience, Inc. announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022.

Dyve Biosciences, Inc. announced that Chuck Harbert, Ph.D., Chief Scientific Officer of Dyve and additional members of management will be attending the Biotechnology Innovation Organization Annual Convention taking place at the San Diego Convention Center, Monday June 13 - Thursday, June 16, 2022.

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, announced its speaker lineup for Antibody Engineering & Therapeutics Europe, which is being held on June 7-9, 2022 in Amsterdam and online.

Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET.

CinCor Pharma, Inc. announced that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat, a highly selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension and chronic kidney disease.

TFF Pharmaceuticals, Inc. announced that President and CEO Glenn Mattes will be participating in the Jefferies Healthcare Conference being held June 8 – 10, 2022 in New York City.

Baudax Bio, Inc. announced that the first cohort has been dosed in a First-in-Man, Phase 1 clinical study evaluating the safety, tolerability and pharmacokinetics of BX2000, a rapid onset, ultra-short acting neuromuscular blocking agent, in healthy volunteers.

NeuExcell Therapeutics announced the publication of a groundbreaking manuscript in the international journal, “Developmental Neurobiology.” NeuExcell Therapeutics’ scientific founder, Professor Gong Chen, along with his research team at Jinan University in Guangzhou, China published a manuscript decoding the molecular mechanisms underlying NeuroD1-induced astrocyte-to-neuron conversion.